Alzheimer's Disease Market and Forecast Analysis 2034: Solanezumab's Failure will Likely Impede the Uptake of Future Beta Amyloid Antibodies - ResearchAndMarkets.com

DUBLIN--()--The "Alzheimer's Disease Market and Forecast Analysis 2034" report has been added to ResearchAndMarkets.com's offering.

Alzheimer's disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, and function. Alzheimer's disease is the most common cause of dementia among older people. Dementia is the loss of cognitive functioning - thinking, remembering, and reasoning - and behavioral abilities, to such an extent that it interferes with a person's daily life and activities. Dementia ranges in severity from mild to the most severe stage, when the person must depend completely on others for basic activities of daily living.

Market Snapshot

  • Solanezumab's failure will likely impede the uptake of future beta amyloid antibodies.
  • The author's survey sheds light on the changing landscape of prescribing patterns in Alzheimer's disease.
  • Alzheimer's disease inflicts a significant burden in the US, Japan, and five major EU markets.
  • A number of commercially successful brands are now reaching the end of their lifecycle.
  • Solanezumab's suspension has not stifled ongoing development of other amyloid-targeting therapies.

Key Topics Covered:

FORECAST: ALZHEIMER'S DISEASE (Published on 21 June 2017)

Overview

Executive Summary

Market Overview And Trends

Market Definition And Methodology

Aducanumab

Aricept (Donepezil)

Crenezumab

Exelon/Exelon Patch (Rivastigmine)

Namenda/Xr (Memantine)

Razadyne (Galantamine)

Rvt-101

Primary Research Methodology

TREATMENT: ALZHEIMER'S DISEASE (Published on 21 June 2017)

Overview

Executive Summary

Primary Research Methodology

Disease Definition And Diagnosis

Patient Segmentation

Country Treatment Trees

Current Treatment Options

Prescribing Trends

Unmet Needs In Alzheimer'S Disease

EPIDEMIOLOGY: ALZHEIMER'S DISEASE (Published on 25 February 2019)

Overview

Disease Background

Methodology

Forecast

Bibliography

Appendix: Mild Cognitive Impairment

MARKETED DRUGS: ALZHEIMER'S DISEASE (Published on 21 June 2017)

Overview

Executive Summary

Product Overview

Product Profile: Aricept

Product Profile: Exelon/Exelon Patch

Product Profile: Namenda

Product Profile: Razadyne

PIPELINE: ALZHEIMER'S DISEASE (Published on 21 June 2017)

Overview

Executive Summary

Clinical Pipeline Overview

Clinical Trial Design

Recently Discontinued Drugs

Additional Pharma Intelligence Pipeline Resources

Product Profile (Late Stage): Lmtx

Product Profile (Late Stage): Rvt-101

Product Profile (Late Stage): Aducanumab

Product Profile (Late Stage): Azeliragon

Product Profile (Late Stage): Crenezumab

Product Profile (Late Stage): Gantenerumab

Product Profile (Late Stage): Verubecestat

For more information about this report visit https://www.researchandmarkets.com/r/sq4lt6

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Alzheimer's Disease Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Alzheimer's Disease Drugs